Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients.
AUTOR(ES)
Ohguro, N
RESUMO
BACKGROUND--Marked variations in cell size (polymegethism) and shape (pleomorphism) are characteristic of the corneal endothelium in diabetic patients and animals. METHOD--Wide field specular microscopy was used to evaluate the clinical efficacy of treating the diabetic corneal endothelium with topical instillation of 0.5% aldose reductase inhibitor, CT-112. RESULTS--Morphological variations (polymegethism and pleomorphism) of the endothelium in eight eyes from eight patients receiving CT-112 resolved within 3 months after initiation of treatment. In contrast, no change in endothelial morphology was noted in five eyes from five patients who received placebo. CONCLUSION--These observations suggest that aldose reductase may be involved in the aetiology of corneal endothelial variations in diabetic patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=505343Documentos Relacionados
- Topical aldose reductase inhibitor.
- Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats.
- Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
- Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.
- The evaluation of corneal endothelial permeability in PERK study patients.
